Affiliation:
1. Resident (Ophthalmology), Dept of Ophthalmology, Army College of Medical Sciences, Delhi Cantt, New Delhi – 110010
Abstract
COVID-19 caused by Sever Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) rst identied at
Wuhan, China has rapidly spread across over 6 continents to become a pandemic and a Public Health
Emergency of International Concern (PHEIC). Till date there is no specic drug for the disease. So there is an imminent
requirement to identify an effective drug to control the outbreak. A number of COVID-19 cases are reported to be associated with
co-bacterial infections especially in immunocompromised individuals. Teicoplanin, a glycopeptide antibiotic, in the past has
been reported to possess antiviral efcacy against coronaviruses such as MERS-CoV and SARS-CoV. In a recently conducted in
vitro study, it has also been observed to possess antiviral activity against SARS-CoV-2. Here we summarize, Teicoplanin, an
antibiotic as a potential therapeutic repurposing option for the treatment of COVID-19, especially in severely ill patients and
those having co-bacterial infections.
Subject
Insect Science,Ecology, Evolution, Behavior and Systematics,Infectious Diseases,Immunology and Allergy,Medicine (miscellaneous),Epidemiology,Molecular Biology,Biochemistry,Infectious Diseases,Pulmonary and Respiratory Medicine,Aerospace Engineering,Mechanical Engineering,Energy Engineering and Power Technology,Aerospace Engineering,Computer Networks and Communications,Software,Electrical and Electronic Engineering,Communication,Artificial Intelligence,Information Systems,Control and Systems Engineering,Software,Urban Studies,Sociology and Political Science,Development